Although antibodies targeting FGFR2 (bemarituzumab, NCT03694522) and FGFR3 (vofatamab, NCT03123055; LY3076226, NCT02529553; MFGR1877S, NCT01363024) are in clinical trials for other cancers, these have yet to be considered for glioblastoma. The gene discussed is FGFR2; the disease is glioblastoma.